These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7786612)

  • 1. The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.
    Torrisi R; Pensa F; Fontana V; Costa A; Decensi A
    Eur J Cancer; 1995; 31A(3):420-1. PubMed ID: 7786612
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
    Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
    Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
    Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of fenretinide in the mammary gland of breast cancer patients.
    Mehta RG; Moon RC; Hawthorne M; Formelli F; Costa A
    Eur J Cancer; 1991; 27(2):138-41. PubMed ID: 1827276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
    Formelli F; Clerici M; Campa T; Di Mauro MG; Magni A; Mascotti G; Moglia D; De Palo G; Costa A; Veronesi U
    J Clin Oncol; 1993 Oct; 11(10):2036-42. PubMed ID: 8410127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic oral administration of fenretinide, as a chemopreventive agent to breast cancer patients, does not affect plasma alpha-tocopherol concentration.
    Formelli F; Clerici M; De Palo G; Costa A; Veronesi U
    Ann Oncol; 1991 Jun; 2(6):446-7. PubMed ID: 1837481
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
    Torrisi R; Parodi S; Fontana V; Pensa F; Casella C; Barreca A; De Palo G; Costa A; Decensi A
    Int J Cancer; 1998 Jun; 76(6):787-90. PubMed ID: 9626341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthetic retinoid fenretinide does not affect circulating hormone concentrations.
    Secreto G; Costa A; Recchiane C; Pizzichetta M; Ballerini P
    Breast Cancer Res Treat; 1988 Dec; 12(3):315-6. PubMed ID: 2976280
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of fenretinide (4-HPR) on dark adaptation.
    Caruso RC; Zujewski J; Iwata F; Podgor MJ; Conley BA; Ayres LM; Kaiser-Kupfer MI
    Arch Ophthalmol; 1998 Jun; 116(6):759-63. PubMed ID: 9639444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
    Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
    Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
    Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
    Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
    Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
    Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
    Serrano D; Baglietto L; Johansson H; Mariette F; Torrisi R; Onetto M; Paganuzzi M; Decensi A
    Clin Cancer Res; 2005 Mar; 11(5):2083-8. PubMed ID: 15756035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoids, breast cancer and NK cells.
    Villa ML; Ferrario E; Trabattoni D; Formelli F; De Palo G; Magni A; Veronesi U; Clerici E
    Br J Cancer; 1993 Nov; 68(5):845-50. PubMed ID: 8217599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of fenretinide-induced apoptosis.
    Hail N; Kim HJ; Lotan R
    Apoptosis; 2006 Oct; 11(10):1677-94. PubMed ID: 16850162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
    Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.